Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Experientia

• Publication date

  1994-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF01952865PMID 8033972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BCG and cancer (first of two parts).

  2010cited by this paper
• Phase-I study of intravenous modified lipid A

  2004cited by this paper
• MHC interaction and T cell recognition of carbohydrates and glycopeptides.

  1992cited by this paper
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

  1992cited by this paper
• Role of gangliosides in active immunotherapy with melanoma vaccine.

  1991cited by this paper
• Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules.

  1991cited by this paper
• Gangliosides as Targets for Monoclonal Antibody Therapy of Cancer

  1990cited by this paper
• Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.

  1990cited by this paper
• ELISA for antibodies to lipid A, lipopolysaccharides and other hydrophobic antigens

  1989cited by this paper
• Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients

  1989cited by this paper
• Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.

  1988cited by this paper
• Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients

  1988cited by this paper
• Escape mechanisms of melanoma from immune system by soluble melanoma antigen.

  1988cited by this paper
• Gangliosides as antigens of human melanoma.

  1988cited by this paper
• Human melanoma antigen O-acetylated ganglioside GD3 is recognized by Cancer antennarius lectin.

  1988cited by this paper
• Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

  1988cited by this paper
• Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.

  1987cited by this paper
• The biological modification of tumor cells as a means of inducing their regression: an overview.

  1986cited by this paper
• Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma.

  1985cited by this paper
• A two-step mechanism for the interaction of Re lipopolysaccharide with erythrocyte membranes.

  1984cited by this paper
• Paralytic poliomyelitis can be eliminated.

  1984cited by this paper
• Enhancement of immunogenicity by incorporation of lipid A into liposomal model membranes and its application to membrane-associated antigens.

  1983cited by this paper
• Membrane lipid composition modulates the binding specificity of a monoclonal antibody against liposomes.

  1982cited by this paper
• Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A.

  1979cited by this paper
• Immunogenicity of leukemia L1210 cells after neuraminidase treatment.

  1972cited by this paper
• Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy.

  1972cited by this paper
• Suppression of tumor growth and induction of specific tumor immunity by intradermal inoculation of a mixture of living tumor cells and live Mycobacterium bovis in syngeneic mice.

  1971cited by this paper

• Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines

  2022cites this paper
• GM3 ganglioside: a novel target for the therapy against melanoma

  2009cites this paper
• Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8+ T cells-mediated protection against melanoma B16 challenge

  2008cites this paper
• Myocardial Protection by Monophosphoryl Lipid A: Potential Mechanisms

  2006cites this paper
• 3'-sialyllactose neoglycoconjugates are not able to provide an immunological response against N-acetyl GM3 ganglioside in mice and chickens

  2004cites this paper
• Einfluß des operativen Traumas auf die Entwicklung pulmonaler Metastasen bei hämatogen zirkulierenden Tumorzellen

  2003cites this paper
• Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate

  2002cites this paper
• Toxicity of a GM3 cancer vaccine inMacaca fascicularis monkey: a 12-month study

  2002cites this paper
• Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model

  2002cites this paper
• A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo

  2001cites this paper
• Characterization of Forssman and Other Antigen/Antibody Systems in Vascularized Mouse Heart to Rat Xenotransplantation

  2001cites this paper
• Adjuvant Activity of Monophosphoryl Lipid A for Nasal and Oral Immunization with Soluble or Liposome-Associated Antigen

  2000cites this paper
• Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).

  1999cites this paper
• Active immunotherapy with allogeneic tumor cell vaccines: present status.

  1998cites this paper
• Ratio of IgG: IgM antibodies to sialyl LewisX and GM3 correlates with tumor growth after immunization with melanoma‐cell vaccine with different adjuvants in mice

  1998cites this paper
• Endothelial‐selectin ligands sialyl Lewisx and sialyl Lewisa are differentiation antigens immunogenic in human melanoma

  1997cites this paper
• Augmentation of natural antiganglioside IgM antibodies in lower motor neuron disease (LMND) and role of CD5+ B cells

  1997cites this paper
• Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Lea, sialyl Lex, GD3 and GM2) better than soluble lysate cancer vaccine

  1997cites this paper
• Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines.

  1997cites this paper
• Effects of the adjuvant MPL + TDM on tumor challenge in the B16 mouse melanoma model.

  1996cites this paper
• Effects of monophosphoryllipid-A on the immunization of mice with keyhole limpet hemocyanin- and muramyldipeptide-ganglioside Gfpt1 conjugates.

  1996cites this paper